DexCom, Inc.

DXCM Healthcare Medical Devices

DexCom, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.7 billion, up 15.6% from fiscal 2024. In the quarter to June 2026, revenue grew 13.1%, EPS grew 41.3%, free cash flow fell 11.7% and total debt was flat, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100; revenue growth for ten consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.

86.06 1.65 −1.88%
Market cap
$33.1B
P/E
33.2×
Fwd P/E
29.8×
Dividend yield
—
F-score
8/9
Altman Z
6.43
Beneish M
−2.70
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
26.00 26.17 30.87 36.37

+8 more quarters

P/S ratio
5.18 5.02 5.56 5.83
P/FCF ratio
18.32 16.92 24.04 24.78
P/Operating CF
95.62 46.01 88.09 39.88
P/B ratio
9.82 8.18 9.43 9.65
EV/Sales
5.19 4.94 5.56 5.54
EV/EBITDA
18.39 18.40 22.27 24.47
EV/FCF
18.37 16.64 24.06 23.55
Current Ratio
1.73 1.95 1.88 1.56
Net Debt/EBITDA
(1.82) (3.64) (1.95) (6.80)
Debt/Equity
0.47 0.42 0.45 0.45
Earnings Yield
3.85% 3.82% 3.24% 2.75%
Free Cash Flow Yield
5.46% 5.91% 4.16% 4.04%
Free Cash Flow per Share
0.48 1.17 0.49 1.48
Book value per Share
6.86 7.68 7.04 6.97
Free Cash Flow
184.50 449.00 192.10 579.40
EV/EBIT
22.66 23.01 28.42 32.16
Other line items

Show all line items

Columns are period end dates